Literature DB >> 6819111

Failure to induce early abortion by huge doses of a superactive LRH agonist in women.

G Skarin, S J Nillius, L Wide.   

Abstract

The possible abortifacient effect of the potent stimulatory luteinizing hormone-releasing hormone analogue D-Ser(TBU)6-EA10-LRH was studied in five women in early pregnancy. Four of them were treated by intravenous injections of the superactive LRH agonist in a dose of 50-125 micrograms t.i.d. for four days (total dose 600-1500 micrograms). The fifth woman discontinued treatment after the first 50 micrograms dose. The treatment was instituted on gestational day 37, 38, 40, 42 and 46. Clinical examinations and frequently taken peripheral venous blood samples for analyses of human chorionic gonadotropin and ovarian steroids were used for monitoring the treatment. No abortifacient effects of these large doses of the superactive LRH agonist were observed and the pregnancies had to be terminated by suction curettage after 10-13 days. Thus, previously described luteolytic effects by superactive LRH agonist are overcome probably by endogenous chorionic gonadotropin in early human pregnancy.

Entities:  

Keywords:  Abortifacient Agents; Abortion, Drug Induced; Abortion, Induced; Biology; Contraception; Contraception Research; Corpus Luteum; Endocrine System; Estradiol; Family Planning; Fertility Control, Postconception; Genitalia; Genitalia, Female; Gonadotropins, Chorionic; Hormones; Luteolytic Effects; Ovary; Physiology; Pituitary Hormone Releasing Hormones--administraction and dosage; Pregnancy; Pregnancy, First Trimester; Progesterone; Reproduction; Urogenital System

Mesh:

Substances:

Year:  1982        PMID: 6819111     DOI: 10.1016/0010-7824(82)90144-5

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  5 in total

1.  Inadvertent exposure of early pregnancy to gonadotropin releasing hormone analogue.

Authors:  A Shulman; M Shilon; C Bahary; J Dor; A Ellenbogen; S Mashiach
Journal:  J Assist Reprod Genet       Date:  1993-07       Impact factor: 3.412

Review 2.  GnRH and its analogues. Current therapeutic applications and new prospects.

Authors:  H M Fraser
Journal:  Drugs       Date:  1984-03       Impact factor: 9.546

3.  Addition of gonadotropin releasing hormone agonist for luteal phase support in in-vitro fertilization: an analysis of 2739 cycles.

Authors:  Erhan Şimşek; Esra Bulgan Kılıçdağ; Pınar Çağlar Aytaç; Gonca Çoban; Seda Yüksel Şimşek; Tayfun Çok; Bülent Haydardedeoğlu
Journal:  J Turk Ger Gynecol Assoc       Date:  2015-06-01

Review 4.  GnRH agonists and antagonists. Current clinical status.

Authors:  M Filicori; C Flamigni
Journal:  Drugs       Date:  1988-01       Impact factor: 9.546

5.  Outcome of pregnancies inadvertently exposed to gonadotropin-releasing hormone analogues (GnRH-a) in early gestation.

Authors:  Y Gonen; M Dirnfeld; H Abramovici
Journal:  J Assist Reprod Genet       Date:  1993-08       Impact factor: 3.412

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.